Ondansetron Kalceks

Ondansetron, the active ingredient in Ondansetron Kalceks, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to prevent nausea and vomiting caused by chemotherapy, postoperative recovery, and radiation therapy in adult patients.

GNH USA supplies Ondansetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution sourced from the European Union market. The product meets EU pharmacopoeial specifications and is manufactured under GMP conditions.

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: prevents and treats acute and delayed nausea and vomiting associated with cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces incidence of nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: mitigates nausea and vomiting caused by therapeutic radiation.

Ondansetron may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhea: loose stools. - Fatigue: feeling of tiredness. Serious or Rare Side Effects: - QT interval prolongation: potential cardiac rhythm disturbance. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: increased liver transaminases.

When prescribing ondansetron, clinicians should consider several precautionary measures to ensure safe use. - Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcemia before use. - Drug interactions: avoid concomitant use with other QT‑prolonging agents when possible. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron can interact with other medicines, affecting its efficacy or safety. Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce ondansetron effectiveness. - Serotonergic agents (e.g., SSRIs, tramadol): increase risk of serotonin syndrome.